PK UNDER-STUDIED DRUGS IN PREGNANCY

妊娠期 PK 尚未研究的药物

• 批准号: 7603488
• 负责人: MARY F HEBERT
• 金额: $ 0.94万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603488
• 关键词: CYP1A2 gene; CYP2C9 gene; CYP2D6 gene; CYP3A4 gene; Chronic Disease; Clinical; Computer Retrieval of Information on Scientific Projects Database; Count; Drug Kinetics; Fetus; Filtration; Funding; Grant; Individual; Institution; Kidney; Morbidity - disease rate; Mothers; Observational Study; Patient currently pregnant; Pharmaceutical Preparations; Physiological; Postpartum Period; Pregnancy; Pregnant Women; Purpose; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; Vitamins; Woman; base; cytochrome P450 3A; dosage; experience; mortality; prenatal

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Medication use is very common during pregnancy. Untreated or inadequately treated chronic illness during pregnancy is associated with significant morbidity and mortality for both the mother and her fetus. On average, women take 3 medications during pregnancy, not counting prenatal vitamins. Very little is known about the pharmacokinetics of medications during pregnancy. The little information that we do have suggests that the physiologic changes that occur during pregnancy (increased renal filtration, increased activity of CYP3A, CYP2D6 and CYP2C9 and decreased activity of CYP1A2) significantly alter the way the body handles drugs during pregnancy and therefore changes the needed dosages of medications during pregnancy. In most cases, obstetricians base the dosage of medications during pregnancy on how the drugs are handled in non-pregnant individuals with the added influence of their clinical experience. The purpose of this pilot observational study is to evaluate the pharmacokinetics of medications that pregnant women are already receiving for therapeutic reasons during pregnancy and compare that to postpartum.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 在怀孕期间，使用药物非常普遍。怀孕期间未经治疗或未接受治疗的慢性病与母亲和她的胎儿的发病率和死亡率显着有关。 平均而言，妇女在怀孕期间服用3种药物，不计算产前维生素。 关于怀孕期间药物的药代动力学知之甚少。 我们确实有很少的信息表明，怀孕期间发生的生理变化（肾过滤增加，CYP3A，CYP2D6和CYP2C9的活性增加以及CYP1A2的活性下降）显着改变了身体在怀孕期间处理药物的方式，因此在怀孕期间需要改变药物剂量。 在大多数情况下，产科医生以怀孕期间的药物剂量为基础，其在非怀孕个体中如何处理临床经验的影响。 这项试点观察性研究的目的是评估孕妇在怀孕期间由于治疗原因而接受的药物药代动力学，并将其与产后进行比较。